▶ 5-AMINO-1MQ · SUBTOPIC · DOSING LITERATURE

5-AMINO-1MQ Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of 5-AMINO-1MQ. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for 5-AMINO-1MQ reports the following route(s) of administration: Oral (in animal studies), Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of 5-AMINO-1MQ.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for 5-AMINO-1MQ of approximately Short plasma half-life (oral bioavailable). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of 5-AMINO-1MQ. Refer to the original publication for full protocol detail.

Kraus D, Yang Q, Kong D, et al. (2014) reports the 5-AMINO-1MQ protocol used in Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity, published in Nature. See the source for the protocol-level dose range, frequency, and duration. link
Neelakantan H, Vance V, Wetzel MD, et al. (2017) reports the 5-AMINO-1MQ protocol used in Selective NNMT inhibitor (5-amino-1MQ) reduces adiposity in DIO mice, published in J Med Chem. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ Is 5-amino-1MQ a peptide?

No. 5-amino-1MQ is a small-molecule research chemical, not a peptide. It is included in the PEPPUDEX because it intersects with the NAD+/SAM/methionine-cycle longevity research that the wider peptide community follows.

▶ Side effects of 5-amino-1MQ?

Limited human safety data. Animal studies report wide therapeutic windows. Theoretical concerns include methyl-donor depletion with chronic dosing.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · Room temperature in sealed container, light-protected

Reconstituted · Stable in aqueous solution; refrigerate

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research chemical.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ 5-AMINO-1MQ OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19